BLCO
Bausch & Lomb Corp
-0.10 (-0.59%)16.97USD39.9K成交股數6.1B市值–本益比(近四季)1.1股價營收比+9.1%營收年增(近四季)2026-10-28下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 1.4B+9% | 1.2B+9% | 1.4B+17% | 1.3B+5% | 1.3B+16% | 1.1B-3% | 1.2B+19% | 1.2B+17% | 1.1B | 1.2B | 1.0B | 1.0B |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 114M | 101M | 94.0M | 95.0M | 96.0M | 86.0M | 84.0M | 84.0M | 82.0M | 80.0M | 82.0M | 85.0M |
| 銷售管理費用 | 588M | 544M | 564M | 528M | 579M | 563M | 511M | 535M | 504M | 483M | 418M | 417M |
| 營業利益 | 83.0M-855% | 33.0M-140% | 112M+160% | 95.0M+265% | −11.0M-283% | −83.0M-269% | 43.0M+7% | 26.0M-40% | 6.0M | 49.0M | 40.0M | 43.0M |
| 營業利益率 | 6.0% | 2.7% | 8.0% | 7.4% | -0.9% | -7.3% | 3.6% | 2.1% | 0.5% | 4.2% | 4.0% | 4.2% |
| 稅後淨利 | −14.0M-77% | −71.0M-67% | −58.0M-1550% | −28.0M-81% | −62.0M-63% | −212M+293% | 4.0M-105% | −151M+372% | −167M | −54.0M | −84.0M | −32.0M |
| 淨利率 | -1.0% | -5.7% | -4.1% | -2.2% | -4.9% | -18.6% | 0.3% | -12.4% | -15.2% | -4.6% | -8.3% | -3.1% |
| 稀釋 EPS | -0.04-78% | -0.20-67% | -0.16-1700% | -0.08-81% | -0.18-63% | -0.60+300% | 0.01-104% | -0.43+378% | -0.48 | -0.15 | -0.24 | -0.09 |
| 稀釋股數 | 357M | 355M | 354M | 354M | 354M | 353M | 354M | 352M | 351M | 351M | 351M | 351M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 367M | 268M | 383M | 310M | 266M | 202M | 329M | 285M | 315M | 331M | 355M | 384M |
| 應收帳款 | 1.2B | 1.1B | 1.2B | 1.1B | 1.1B | 1.0B | 943M | 986M | 920M | 839M | 783M | 791M |
| 存貨 | 999M | 977M | 976M | 1.0B | 1.1B | 1.0B | 1.1B | 1.1B | 1.1B | 1.0B | 754M | 699M |
| 總資產 | 13.9B | 13.8B | 14.0B | 13.8B | 13.8B | 13.4B | 13.5B | 13.3B | 13.3B | 13.4B | 13.1B | 11.3B |
| 有息負債 | 5.0B | 5.0B | 5.0B | 4.9B | 4.9B | 4.8B | 4.6B | 4.6B | 4.6B | 4.5B | 4.4B | 2.6B |
| 總負債 | 7.4B | 7.3B | 7.5B | 7.3B | 7.3B | 7.0B | 6.9B | 6.7B | 6.6B | 6.5B | 6.2B | 4.3B |
| 股東權益 | 6.4B | 6.4B | 6.4B | 6.4B | 6.4B | 6.4B | 6.6B | 6.5B | 6.7B | 6.9B | 6.8B | 7.0B |
| 負債比 | 53.5% | 53.2% | 53.5% | 53.0% | 52.9% | 52.1% | 50.7% | 50.3% | 49.4% | 48.5% | 47.3% | 37.9% |
| 淨現金(現金 − 有息負債) | −4.7B | −4.7B | −4.6B | −4.6B | −4.7B | −4.6B | −4.3B | −4.3B | −4.2B | −4.2B | −4.1B | −2.2B |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 32.0M-228% | – | – | – | −25.0M | – | – | 41.0M | – | – | – |
| 資本支出 | – | 100M | – | – | – | 110M | – | – | 67.0M | – | – | – |
| 自由現金流 | – | −68.0M-50% | – | – | – | −135M | – | – | −26.0M | – | – | – |
| 折舊攤銷 | – | 101M | – | – | – | 106M | – | – | 110M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -5.5% | – | – | – | -11.9% | – | – | -2.4% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 5.1B
| Vision Care | 2.9B | 57.3% | +6.7% |
|---|---|---|---|
| Pharmaceuticals | 1.3B | 25.2% | +6.2% |
| Surgical | 894M | 17.5% | +6.0% |
地區2025 年度 · 3.3B
| United Statesand Puerto Rico | 2.5B | 78.1% | +5.5% |
|---|---|---|---|
| 德國 | 164M | 5.0% | +7.9% |
| 英國 | 137M | 4.2% | +3.8% |
| 加拿大 | 135M | 4.1% | +6.3% |
| 義大利 | 102M | 3.1% | +12.1% |
| 西班牙 | 101M | 3.1% | +9.8% |
| 墨西哥 | 75.0M | 2.3% | 0.0% |
| 其他國家 小計 | 777M | 23.8% | +9.1% |
| 中國 小計 | 358M | 11.0% | 0.0% |
| 法國 小計 | 246M | 7.5% | +8.4% |
| 日本 小計 | 186M | 5.7% | +3.3% |
| RU 小計 | 148M | 4.5% | +23.3% |
產品／服務2025 年度 · 10.2B
| 產品 | 5.1B | 49.8% | +6.4% |
|---|---|---|---|
| Device Products | 1.9B | 18.8% | +6.8% |
| Overthe Counter Products | 1.8B | 18.0% | +6.4% |
| Pharmaceutical Products | 1.1B | 10.6% | +11.6% |
| Brandedand Other Generic Products | 243M | 2.4% | -13.5% |
| Product And Service Other | 21.0M | 0.2% | +23.5% |
| Other Revenues | 21.0M | 0.2% | +23.5% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 5.1B | +6.5% | −360M | -7.1% | -1.02 | −66.0M |
| FY2024 | 4.8B | +15.6% | −317M | -6.6% | -0.90 | −59.0M |
| FY2023 | 4.1B | +10.0% | −260M | -6.3% | -0.74 | −198M |
| FY2022 | 3.8B | +0.1% | 6.0M | 0.2% | 0.02 | 170M |
| FY2021 | 3.8B | +10.3% | 182M | 4.8% | 0.52 | 680M |
| FY2020 | 3.4B | – | −18.0M | -0.5% | -0.05 | 269M |